The European market for EP mapping and ablation devices will experience moderate growth through 2029, particularly in the diagnostic and ablation catheter segments, largely as a result of increasing ablation volumes. However, the COVID-19 global pandemic will have a significant impact on the Europe EP mapping and ablation device market, resulting in lost procedure volumes in the short term followed by a period of recovery.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for EP mapping and ablation devices in Europe across a 10-year period.
Expansion of the European EP mapping and ablation device market will be driven by increasing procedure volumes, particularly in the AF indication.
How fast are AF treatment volumes changing, and how does AF treatment volume growth compare to other arrhythmia types?
How will the results of the CABANA and CASTLE-AF trials affect AF procedure growth? Specifically, will reimbursement decision-making bodies use subgroup analysis from the CABANA trial to inform which patients to reimburse for AF ablation?
How will shifting physician opinion on ablation techniques for treating AF affect device use?
The COVID-19 pandemic will have a significant impact on the European EP mapping and ablation devices market.
To what extent are the EP ablation procedures being postponed in Europe?
When is the recovery of the procedures expected to begin?
The reimbursement landscape for EP mapping and ablation devices differs between European countries.
How will this affect the adoption of advanced devices that command a premium price?
What strategies can companies adopt to address the increasing cost consciousness among health care facilities?
The reprocessing of EP catheters continues to affect the EP catheter market.
To what extent are institutions turning to reprocessed diagnostic and ablation catheters in order to lower costs?
Which catheters are reprocessed, and what effect does device reprocessing have on market revenues?
Will the COVID-19 pandemic have an effect on the reprocessing of the EP catheters?
- Electrophysiology Mapping And Ablation Devices - Market Insights - Europe
Author(s): Suraj Nair, Masters in Bioprocess Technology
Suraj Nair is a Research Associate within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in the Electrophysiology Mapping and Ablation Devices Market. Suraj holds a Master’s degree in Bioprocess Technology from the Institute of Chemical Technology, Mumbai and has a prior experience of working in the biopharmaceutical industry for two years and in the market research industry for medical devices for a year.